For example, in the context of EGFR-mutated lung cancer, as a model for targeted molecular therapy, the identification of resistance to first-generation of tyrosine kinase inhibitors (TKIs) revealed a secondary mutation in EGFR that prompted the development of third-generation inhibitors, such as Osimertinib specifically designed to target EGFR-T790M (119). This evidence concerns the gene EGFR and lung carcinoma.